Sirolimus in Treating Patients With Advanced Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

September 30, 2008

Study Completion Date

June 30, 2009

Conditions
Pancreatic Cancer
Interventions
DRUG

sirolimus

Treatment with rapamycin will begin on Day 1 at a single flat dose level of 5 mg/day. Rapamycin will be administered continuously without interruption through all cycles in an outpatient setting. Each cycle will last 28 days.

Trial Locations (1)

21231-2410

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT00499486 - Sirolimus in Treating Patients With Advanced Pancreatic Cancer | Biotech Hunter | Biotech Hunter